- Home
- GMED
GMED
Globus Medical Inc.
as of 03-24-2026 3:53pm EST
$86.16
$1.05
-1.20%
Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States. It also has its presence internationally.
| Founded: | 2003 | Country: | United States |
| Employees: | N/A | City: | AUDUBON |
| Market Cap: | 12.9B | IPO Year: | 2012 |
| Target Price: | $100.42 | AVG Volume (30 days): | 947.4K |
| Analyst Decision: | Buy | Number of Analysts: | 14 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 3.92 | EPS Growth: | 422.67 |
| 52 Week Low/High: | $51.79 - $101.40 | Next Earning Date: | 05-07-2026 |
| Revenue: | $2,938,931,000 | Revenue Growth: | 16.65% |
| Revenue Growth (this year): | 11.13% | Revenue Growth (next year): | 6.28% |
| P/E Ratio: | 21.94 | Index: | N/A |
| Free Cash Flow: | 588.8M | FCF Growth: | +45.30% |
Stock Insider Trading Activity of Globus Medical Inc. (GMED)
Huller Kelly
Sell
EVP, GC, Corporate Secretary
GMED Feb 25, 2026
Avg Cost/Share
$94.50
Shares
20,000
Total Value
$1,890,000.00
Owned After
0
SEC Form 4
Huller Kelly
Sell
EVP, GC, Corporate Secretary
GMED Feb 12, 2026
Avg Cost/Share
$87.67
Shares
10,000
Total Value
$876,700.00
Owned After
0
SEC Form 4
Norwalk Leslie V
Sell
Director
GMED Jan 8, 2026
Avg Cost/Share
$101.10
Shares
2,000
Total Value
$202,200.00
Owned After
10,419
SEC Form 4
Kline Kyle
Sell
Senior Vice President, CFO
GMED Jan 8, 2026
Avg Cost/Share
$101.10
Shares
3,594
Total Value
$363,353.40
Owned After
0
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Huller Kelly | GMED | EVP, GC, Corporate Secretary | Feb 25, 2026 | Sell | $94.50 | 20,000 | $1,890,000.00 | 0 | |
| Huller Kelly | GMED | EVP, GC, Corporate Secretary | Feb 12, 2026 | Sell | $87.67 | 10,000 | $876,700.00 | 0 | |
| Norwalk Leslie V | GMED | Director | Jan 8, 2026 | Sell | $101.10 | 2,000 | $202,200.00 | 10,419 | |
| Kline Kyle | GMED | Senior Vice President, CFO | Jan 8, 2026 | Sell | $101.10 | 3,594 | $363,353.40 | 0 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K BUY Feb 24, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K BUYFeb 24, 2026 · 100% conf.
AI Prediction BUY
1D
+6.16%
$97.58
Act: +4.68%
5D
+8.78%
$99.99
Act: -0.24%
20D
+8.09%
$99.36
Price: $91.92 Prob +5D: 100% AUC: 1.000
0001628280-26-011124
gmed-202602240001237831FALSE00012378312026-02-242026-02-24
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2026
GLOBUS MEDICAL, INC.
(Exact name of registrant as specified in charter)
DELAWARE
001-3562104-3744954 (State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification No.)
2560 GENERAL ARMISTEAD AVENUE, AUDUBON, PA 19403-5214
(Address of principal executive offices) (Zip Code) (610) 930-1800 (Registrant’s telephone number, including area code) Not Applicable (Former Address)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolsName of exchange on which registered Class A Common Stock, par value $.001 per shareGMEDNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02. Results of Operations and Financial Condition. On February 24, 2026, Globus Medical, Inc. (the “Company”) issued a press release reporting, among other things, its sales and operating results for the three and twelve-month periods ended December 31, 2025. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. In accordance with general instruction B.2 to Form 8-K, the information included in this Item 2.02, and the exhibit attached hereto, shall be deemed to be “furnished” and shall not be deemed to be “filed” with the Securities and Exchange Commission for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
Exhibit No.Description
99.1Press Release dated February 24, 2026
104The cover page from this Current Report on Form 8-K, formatted as Inline XBRL.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
GLOBUS MEDICAL, INC.
(Registrant)
Dated:February 24, 2026/s/ KYLE R. KLINE
Kyle R. Kline
Chief Financial Officer (Principal Financial Officer) Senior Vice President
2025 Q4 Q4 2025 Earnings
8-K BUY Jan 7, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K BUYJan 7, 2026 · 100% conf.
AI Prediction BUY
1D
+6.16%
$97.58
Act: +4.68%
5D
+8.78%
$99.99
Act: -0.24%
20D
+8.09%
$99.36
Price: $91.92 Prob +5D: 100% AUC: 1.000
0001628280-26-001189
gmed-202601070001237831FALSE00012378312026-01-072026-01-07
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2026
GLOBUS MEDICAL, INC.
(Exact name of registrant as specified in charter)
DELAWARE
001-3562104-3744954 (State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification No.)
2560 GENERAL ARMISTEAD AVENUE, AUDUBON, PA 19403-5214
(Address of principal executive offices) (Zip Code) (610) 930-1800 (Registrant’s telephone number, including area code) Not Applicable (Former Address) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolsName of exchange on which registered Class A Common Stock, par value $.001 per shareGMEDNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02. Results of Operations and Financial Condition.
On January 7, 2026, Globus Medical, Inc. (the “Company”) issued a press release reporting the Company’s preliminary unaudited net sales results for the three-month period and fiscal year ended December 31, 2025. The press release also included preliminary guidance for certain financial measures for the fiscal year ending December 31, 2026. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.
In accordance with general instruction B.2 to Form 8-K, the information included in this Item 2.02, and the exhibit attached hereto, shall be deemed to be “furnished” and shall not be deemed to be “filed” with the Securities and Exchange Commission for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
Exhibit No.Description
99.1Press Release dated January 7, 2026
104The cover page from this Current Report on Form 8-K, formatted as Inline XBRL.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
GLOBUS MEDICAL, INC.
(Registrant)
Dated:January 7, 2026/s/ KYLE KLINE
Kyle Kline
Chief Financial Officer
(Principal Financial Officer)
Senior Vice President
2025 Q3 Q3 2025 Earnings
8-K Nov 6, 2025
2025
Q3
Q3 2025 Earnings
8-KNov 6, 2025
0001237831-25-000029
gmed-20251106x8k
false0001237831DE00012378312025-11-062025-11-06
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 6, 2025
GLOBUS MEDICAL, INC.
(Exact name of registrant as specified in charter)
DELAWARE
001-35621
04-3744954
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
2560 GENERAL ARMISTEAD AVENUE, AUDUBON, PA 19403-5214
(Address of principal executive offices) (Zip Code)
(610) 930-1800 (Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbols Name of exchange on which registered
Class A Common Stock, par value $.001 per share
GMED
New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 2.02. Results of Operations and Financial Condition.
On November 6, 2025, we issued a press release reporting, among other things, our sales and operating results for the three and nine month period ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this report.
In accordance with general instruction B.2 to Form 8-K, the information included in this Item 2.02, and the exhibits attached hereto, shall be deemed to be “furnished” and shall not be deemed to be “filed” with the Securities and Exchange Commission for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.
Item 9.01. Financial Statements and Exhibits.
Exhibit No.
Description
99.1
Press Release dated November 6, 2025
104
The cover page from this Current Report on Form 8-K, formatted as Inline XBRL.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
GLOBUS MEDICAL, INC.
(Registrant)
Dated: November 6, 2025 /s/ KYLE KLINE
Kyle Kline
Chief Financial Officer
(Principal Financial Officer)
Senior Vice President
Latest Globus Medical Inc. News
GMED Breaking Stock News: Dive into GMED Ticker-Specific Updates for Smart Investing
Compare GMED vs Leading Stocks
See how GMED stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "GMED Globus Medical Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.